Latest filing published 07 Dec 2021 for Pear Therapeutics, Inc..
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Zack Lynch: trading record in brief
Zack Lynch (board member) discloses dealings in Pear Therapeutics, Inc. to SEC (Form 4). The record holds 3 filings, all for trades on 3 December 2021.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 7 December 2021 came the latest disclosure, a share grant for €88k in Pear Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Companies and markets linked to Zack Lynch
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 1,084,914 sharesClass A Common StockSEC:0001062993-21-012390:0
1 of 1 declaration
